Method for cancer cell reprogramming
AssigneeStc.Unm
InventorsAlexandre Chigaev, Larry A. Sklar, Dominique Perez
Life of this patent
Estimating the term…
Abstract
In one embodiment, the invention provides a method of inhibiting cAMP efflux and increasing intracellular cAMP in a subject who suffers from, or who is at risk of developing, a cancer by administering to the subject a therapeutically-effective amount of a cAMP efflux inhibitor. Novel compounds, pharmaceutical compositions, diagnostics and screening methods are also provided.
Claims27
A method of determining whether a composition of unknown activity against a cancer is effective in the treatment of said cancer, the method comprising contacting a test eukaryotic cancer cell sample with the composition, measuring cellular cAMP efflux, and comparing measured cellular cAMP efflux of said test cancer cell sample with levels of cAMP efflux in a control eukaryotic cancer cell sample, wherein reduced expression levels of cAMP efflux of said test sample when compared to control expression levels indicates that the composition is effective in the treatment of said cancer.
A method of determining the effectiveness of cancer therapy in a patient in need with an anti-cancer composition, the method comprising administering said composition to said patient and measuring cAMP in the urine of said patient at least once during a course of therapy, wherein a decrease in measured c-AMP over the course of therapy evidences effectiveness of the therapy in the treatment of said patient's cancer.
A method of determining whether a composition of unknown activity against a cancer is effective in the treatment of said cancer, the method comprising contacting a test eukaryotic cancer cell sample with the composition, measuring cellular F-cAMP efflux in said test cancer cell sample, and comparing measured cellular F-cAMP efflux in said test cancer cell sample with levels of F-cAMP efflux in a control eukaryotic cancer cell sample, wherein reduced expression levels of F-cAMP efflux when compared to control or standard expression levels indicates that the composition is effective in the treatment of said cancer.
A method of determining whether a patient with cancer is a candidate for cancer therapy comprising obtaining cancer tissue, including cancer cells from said patient, exposing said tissue and/or cells to said cancer therapy and measuring F-cAMP efflux from said cells wherein a reduction of F-cAMP efflux from said cells compared to a standard evidences that the patient will respond to said proposed treatment.
Dependencies are inferred from the claim text.